Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 242
Filtrar
1.
Rev Sci Instrum ; 92(2): 025115, 2021 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-33648082

RESUMO

Atomic layer deposition (ALD) is an industrially applied technique for thin film deposition. The vast majority of processes target flat substrates rather than powders. For ALD on powders, new processes are needed, as different reaction conditions are required. Here, two setups are described in detail, which enhance the ALD process development for powders. The first setup described is capable of directly measuring the vapor pressure of a given precursor by a capacitance diaphragm gauge. Promising precursors can be pre-selected, and suitable precursor saturation temperatures can be determined. The second setup consists of four parallel reactors with individual temperature zones to screen the optimal ALD temperature window in a time efficient way. Identifying the precursor saturation temperature beforehand and subsequently performing the first ALD half cycle in the parallel setup at four different reactor temperatures simultaneously will drastically reduce process development times. Validation of both setups is shown for the well-known ALD precursors, trimethylaluminum to deposit aluminum oxide and diethyl zinc to deposit zinc oxide, both on amorphous silica powder.

2.
Br J Psychiatry ; 182: 319-23, 2003 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-12668407

RESUMO

BACKGROUND: Polyuria is common in patients with bipolar disorder treated with lithium. However, the risk factors for polyuria in these patients have not been established. AIMS: To estimate the prevalence of polyuria associated with the use of lithium and to identify additional risk factors. METHOD: A 4-month prospective follow-up study in an out-patient lithium clinic. The 75 participants were asked to provide 24-h urine samples; polyuria was defined as a urine volume greater than 3 litres per 24 h. Risk factors examined included demographic variables, medications and medical comorbidities. RESULTS: The prevalence of polyuria among lithium users was 37%. Concomitant use of serotonergic antidepressants was strongly associated with polyuria (odds ratio 4.25, 95% CI 1.15-15.68) compared with patients not using these agents. CONCLUSIONS: Our data confirm the high prevalence of lithium-induced polyuria. Physicians should be aware that concurrent use of serotonergic antidepressants and lithium significantly enhances the risk of its occurrence. Although limited polyuria is not harmful, it may be troublesome for the patient. In many cases cessation of lithium therapy is not an option because of difficulty in controlling the manic or depressive symptoms.


Assuntos
Antipsicóticos/efeitos adversos , Lítio/efeitos adversos , Poliúria/induzido quimicamente , Adulto , Antidepressivos/uso terapêutico , Transtorno Bipolar/tratamento farmacológico , Transtorno Depressivo/tratamento farmacológico , Quimioterapia Combinada , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Fatores de Risco , Serotoninérgicos/uso terapêutico , Resultado do Tratamento
3.
Gut ; 47(2): 281-7, 2000 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-10896923

RESUMO

BACKGROUND: In patients with alcoholic liver cirrhosis, endotoxaemia is a frequent finding. Unknown mechanisms, however, prevent typical clinical symptoms of endotoxaemia in many patients. METHODS: We determined plasma levels of pro- and anti-inflammatory mediators, ex vivo cytokine secretion capacity, and expression of tumour necrosis factor (TNF) receptors on phagocytic blood cells in 49 patients with alcoholic cirrhosis and 41 age matched healthy controls. RESULTS: In addition to increased levels of proinflammatory cytokines in cirrhotic patients, we observed consistent upregulation of the anti-inflammatory mediators interleukin 10 (IL-10) (plasma 15.75 (1. 6) v 6.6 (1.3) pg/ml (p<0.001); ex-vivo 108.4 (22.0) v 40.1 (7.4) pg/ml (p<0.05)), interleukin 1 receptor antagonist (plasma 527.1 (83) v 331.4 (56) pg/ml (p<0.05); ex vivo 19.9 (3.4) v 10.2 (2.7) ng/ml (p<0.01)), and soluble TNF receptors (sTNF-R) in plasma (sTNF-RI 3157.2 (506.2) v 607.9 (300.3) pg/ml; sTNF-RII 3331.0 (506. 2) v 1066.4 (225.1) pg/ml (p<0.001 for both)). Desensitisation at the target cell level was indicated by reduced expression of TNF receptor I on granulocytes (64.8 (6.5) v 40.1 (7.3)% positive cells; p<0.05) and unaltered plasma levels of soluble E-selectin. CONCLUSION: In patients with alcoholic liver cirrhosis, upregulation of the pro- and anti-inflammatory cytokine system and simultaneous desensitisation of effector cells could explain the restricted systemic inflammatory response to chronic endotoxaemia. This alteration in immune status may lead to impairment of host defences against infections which are frequent complications of alcoholic cirrhosis.


Assuntos
Endotoxinas/imunologia , Tolerância Imunológica , Interleucina-10/imunologia , Cirrose Hepática Alcoólica/imunologia , Receptores de Interleucina-1/imunologia , Receptores do Fator de Necrose Tumoral/imunologia , Adulto , Estudos de Casos e Controles , Feminino , Granulócitos/imunologia , Humanos , Interleucina-10/sangue , Cirrose Hepática Alcoólica/sangue , Masculino , Pessoa de Meia-Idade , Receptores de Interleucina-1/antagonistas & inibidores , Receptores de Interleucina-1/sangue , Receptores do Fator de Necrose Tumoral/sangue , Linfócitos T Reguladores/imunologia , Regulação para Cima
4.
Nephrol Dial Transplant ; 15(8): 1155-61, 2000 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-10910438

RESUMO

BACKGROUND: It has been suggested that urinary excretion of the vasopressin-dependent water channel of the kidney collecting duct, aquaporin-2 (AQP2), reflects renal vasopressin action and might be used clinically. It is unclear, however, what relation exists between urine osmolality and urinary excretion of AQP2 (UAQP2) and it is unknown whether UAQP2 is influenced by hyperosmolality of urine or tubular flow rates. METHODS: We measured urine osmolality and UAQP2 in healthy volunteers in various conditions: (i) overnight dehydration continued during the day, (ii) after infusion of 700 ml hypertonic saline (NaCl 2.5%), and (iii) after intranasal administration of 40 microg 1-desamino-8-D-arginine vasopressin (DDAVP). The last two tests were performed after water loading. In addition, a DDAVP test was performed, after administration of frusemide. RESULTS: After overnight dehydration, the urine osmolality increased from 888+/-18 to 1004+/-17 mosmol/kg during additional hours of thirsting, whereas UAQP2 doubled from 140+/-45 to 285+/-63 fmol AQP2/micromol creatinine. Infusion of hypertonic saline increased urine osmolality from 70+/-3 to 451+/-68 mosmol/kg, while UAQP2 remained almost zero. Urine osmolality increased from 101+/-17 to 860+/-30 mosmol/kg after administration of DDAVP, with a parallel increase in UAQP2 from 32+/-14 to 394+/-81 fmol AQP2/micromol creatinine. Pre-treatment with frusemide attenuated the increase in urine osmolality, but had no effect on UAQP2 after DDAVP. CONCLUSIONS: Our data demonstrate that a simple relationship between urine osmolality and UAQP2 does not exist. Therefore, random or once-only measurements of UAQP2 as an index of renal vasopressin action are not useful. In contrast, intranasal application of DDAVP resulted in a parallel rise in urine osmolality and UAQP2. Therefore this test might be useful in studying patients with urine concentration defects. The DDAVP-frusemide test revealed that the release of AQP2 into urine is not caused by hypertonicity of tubular fluid.


Assuntos
Aquaporinas/urina , Adulto , Aquaporina 2 , Aquaporina 6 , Desamino Arginina Vasopressina/farmacologia , Desidratação/urina , Diuréticos/farmacologia , Feminino , Furosemida/farmacologia , Humanos , Masculino , Concentração Osmolar , Valores de Referência , Fármacos Renais/farmacologia , Solução Salina Hipertônica/farmacologia , Urina/química
5.
Liver ; 20(6): 427-36, 2000 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-11169056

RESUMO

BACKGROUND: Combination therapy with interferon alpha (IFNalpha) plus ribavirin has been shown to improve the sustained response rate in patients with chronic hepatitis C but there is little information regarding the lengths of time for this therapeutic regimen. In this study we therefore tried to evaluate whether the analysis of different virological parameters could provide new clues with respect to the early determination of the efficacy of this form of combination therapy. Furthermore, we also examined whether short-term induction combination therapy followed by IFNalpha alone is more effective than monotherapy in mounting an initial as well as a sustained virological response. METHODS: 185 patients with histologically proven chronic hepatitis C (mean age 42 years (range 19-65 years); 110 males, 75 females) were enrolled in the study. The patients were randomly assigned to receive, over the first 12 weeks, either interferon alpha 2a 6 million units (MU) three times weekly plus ribavirin 14 mg/kg per day (n=93) or the same dose of IFNalpha alone (n=92). Patients with a virological response (serum HCV RNA undetectable) after 12 weeks were subsequently treated with 3 MU IFNalpha alone thrice weekly for a further 40 weeks. Otherwise, treatment was discontinued. After the end of treatment, patients were followed up for 24 weeks. RESULTS: Patient characteristics at baseline were not significantly different in the two treatment groups. An initial virological response at week 12 was seen in 61 (66%) patients receiving IFNalpha plus ribavirin and in 44 (48%) being treated with IFNalpha alone (p=0.015) and this improvement in the response rate was mainly restricted to HCV genotype 1-infected patients (58% vs. 38%). In contrast, end-of-treatment (week 52) and sustained virological response rates were similar in both groups (37% vs. 29% and 26% vs. 17% [p=0.1], respectively). Interestingly, patients with HCV genotype 3, however, clearly benefited from short-term combination therapy. Thus, sustained virological response rates in these patients significantly increased from 25% (IFNalpha monotherapy) to 59% (combination therapy) (p=0.05). CONCLUSIONS: Short-term combined therapy for 12 weeks is more effective than the monotherapy with respect to the induction of an initial virological response but this effect applies only to genotype 1-infected patients. However, there is no significant difference between both therapeutic schedules with regard to the induction of sustained response. Although HCV genotype 3-infected patients seem to benefit from this short-term combined therapy, prolonged combined therapy may be necessary in HCV genotype 1-infected patients.


Assuntos
Antivirais/uso terapêutico , Hepatite C Crônica/tratamento farmacológico , Interferon-alfa/uso terapêutico , Ribavirina/uso terapêutico , Adulto , Idoso , Quimioterapia Combinada , Feminino , Hepacivirus/genética , Hepacivirus/isolamento & purificação , Hepatite C Crônica/virologia , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , RNA Viral/análise , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Fatores de Tempo , Resultado do Tratamento , Viremia/tratamento farmacológico
6.
Eur J Med Res ; 4(4): 131-4, 1999 Apr 27.
Artigo em Inglês | MEDLINE | ID: mdl-10205287

RESUMO

BACKGROUND: Pneumocystis carinii pneumonia (PCP) is one of the most common AIDS defining diagnoses. METHODS: In a prospective observational trial all cases of Pneumocystis carinii pneumonia (PCP) were evaluated. Patients with and without PCP-prophylaxis were compared for symptoms, efficacy, side effects and mortality at week 4 and 26. RESULTS: 293 patients developed a PCP episode. Patients with no prophylaxis had a significant lower CD4 cell count and a more severe clinical status at time of diagnosis. This was pronounced in the group with first positive HIV test at time of diagnosis. There was no difference in the rate of successful treatment between both groups. At week four a tendency to a better survival in the group with prophylaxis was observed, however this changed to a trend to a better survival at week 26 for the group without prophylaxis. CONCLUSION: Even in the era of highly active antiretroviral treatment many patients present with PCP. Nearly 60% of patients presented without antiretroviral treatment or PCP-prophylaxis. Nearly 25% of all patients had their first HIV-test at time of PCP diagnosis.


Assuntos
Infecções Oportunistas Relacionadas com a AIDS/epidemiologia , Pneumonia por Pneumocystis/epidemiologia , Infecções Oportunistas Relacionadas com a AIDS/complicações , Infecções Oportunistas Relacionadas com a AIDS/prevenção & controle , Adulto , Fármacos Anti-HIV/uso terapêutico , Feminino , Alemanha/epidemiologia , Infecções por HIV/diagnóstico , Infecções por HIV/tratamento farmacológico , Humanos , Masculino , Pessoa de Meia-Idade , Pneumonia por Pneumocystis/complicações , Pneumonia por Pneumocystis/prevenção & controle , Estudos Prospectivos
7.
J Am Soc Nephrol ; 9(9): 1553-9, 1998 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-9727361

RESUMO

Glycosylation has been shown to be important for proper routing and membrane insertion of a number of proteins. In the collecting duct, aquaporin-2 (AQP2) is inserted into the apical membrane after stimulation of vasopressin type-2 receptors and retrieved into an endosomal compartment after withdrawal of vasopressin. The extent of glycosylation of AQP2 in human kidney and urine and the effects of deglycoylation on routing of AQP2 in an AQP2-transfected Madin-Darby canine kidney cell line (clone WT10) were investigated. Semiquantitative immunoblotting of human kidney membranes and urine showed an AQP2 glycosylation of 35 to 45% for medulla, papilla, and urine, with low variation among individuals. The 1-desamino-8-D-arginine vasopressin-induced transcellular osmotic water permeability (Pf) of WT10 cells by a factor of 2.6 +/- 0.2 was reduced to 1.5 +/- 0.1 after pretreatment with the glycosylation inhibitor tunicamycin. However, when WT10 cells were incubated with 8-br-cAMP, the Pf increased by a factor 2.8 +/- 0.2 and by 2.9 +/- 0.2 after prior incubation with tunicamycin. Immunoblot analyses revealed that in WT10 cells, 34% of AQP2 is glycosylated, which was reduced to 2% after tunicamycin treatment. Surface biotinylation and subsequent semiquantitative immunoblotting revealed that stimulation by cAMP increased the level of AQP2 in the apical membrane of WT10 cells 1.5-fold. independent of the presence of tunicamycin. However, in tunicamycin-treated WT10 cells, all AQP2 in the apical membrane was unglycosylated, whereas in untreated cells 30% of AQP2 in the apical membrane was glycosylated. These results prove that glycosylation has no function in the routing of AQP2 in Madin-Darby canine kidney cells.


Assuntos
Aquaporinas/análise , Água Corporal/metabolismo , Membrana Celular/metabolismo , Rim/metabolismo , Vasopressinas/metabolismo , Animais , Aquaporina 2 , Aquaporina 6 , Transporte Biológico , Permeabilidade da Membrana Celular/efeitos dos fármacos , Células Clonais/efeitos dos fármacos , Células Clonais/metabolismo , AMP Cíclico/metabolismo , AMP Cíclico/farmacologia , Cães , Glicosilação/efeitos dos fármacos , Humanos , Immunoblotting , Rim/citologia , Rim/efeitos dos fármacos , Concentração Osmolar , Valores de Referência , Propriedades de Superfície , Tunicamicina/farmacologia , Urina/química , Vasopressinas/farmacologia
8.
Hepatology ; 27(3): 881-6, 1998 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-9500723

RESUMO

Acute hepatitis A superimposed on chronic liver disease (CLD) has been associated with severe or fulminant hepatitis. An open, multicenter study was performed to compare the safety and immunogenicity of an inactivated hepatitis A vaccine in patients with CLD with that in healthy subjects. A secondary objective was to compare the safety of the hepatitis A vaccine with that of a commercial hepatitis B vaccine in subjects with chronic hepatitis C. A total of 475 subjects over the age of 18 years were enrolled into 1 of 5 groups according to history, serological data, and previous diagnosis. Patients in groups 1 (healthy adults), 2 (chronic hepatitis B), 3 (chronic hepatitis C), and 5 (other CLD not caused by viral hepatitis) were vaccinated with two doses of inactivated hepatitis A vaccine, 6 months apart. Patients in group 4 (chronic hepatitis C) received 3 doses of a recombinant hepatitis B vaccine, according to a 0-, 1-, and 6-month schedule. Local injection-site symptoms were the most common reactions reported following vaccination in all groups (35.5% of all doses), with the hepatitis B vaccine eliciting fewer injection-site symptoms than the hepatitis A vaccine (19.8% compared with 37.5%). Although a higher percentage of healthy subjects (93%) seroconverted after a single dose of the hepatitis A vaccine than did subjects with chronic hepatitis C (73.7%) or CLD of nonviral etiologies (83.1%), more than 94% of all vaccinees were seropositive for anti-HAV after the complete vaccination course. At each time point, a lower geometric mean concentration of anti-HAV was observed for each group of CLD patients compared with the healthy control subjects. In conclusion, hepatitis A vaccine was well tolerated and induced a satisfactory immune response in patients with chronic hepatitis B, chronic hepatitis C, and miscellaneous CLD.


Assuntos
Vírus da Hepatite A Humana/imunologia , Hepatopatias/imunologia , Vacinas contra Hepatite Viral/efeitos adversos , Adolescente , Adulto , Idoso , Doença Crônica , Feminino , Vacinas contra Hepatite A , Hepatite B/imunologia , Hepatite C/imunologia , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Vacinação , Vacinas contra Hepatite Viral/imunologia
9.
Z Arztl Fortbild Qualitatssich ; 92(10): 677-80, 1998 Dec.
Artigo em Alemão | MEDLINE | ID: mdl-10028595

RESUMO

The availability of vaccines had made on Hepatitis A as well as Hepatitis B an avoidable illnesses. However, there is a lack of knowledge referring to the epidemiological situation. This might be due to the physician's as well as the patient's underestimation of the risk of a new infection but also insufficient knowledge about indication, management of vaccination, adverse events and cost effectiveness might. Vaccination against Hepatitis A and B produce a longlasting immunisation which is indicated in every age. A combined vaccination for both infectious diseases are effective and support the compliance. The role of the family physician is decisive in the management of a sufficient vaccination strategy.


Assuntos
Hepatite A/prevenção & controle , Vacinas contra Hepatite B/administração & dosagem , Hepatite B/prevenção & controle , Vacinas contra Hepatite Viral/administração & dosagem , Adulto , Criança , Alemanha , Hepatite A/transmissão , Vacinas contra Hepatite A , Hepatite B/transmissão , Vacinas contra Hepatite B/efeitos adversos , Humanos , Fatores de Risco , Vacinas Combinadas/administração & dosagem , Vacinas Combinadas/efeitos adversos , Vacinas contra Hepatite Viral/efeitos adversos
10.
J Hepatol ; 26(3): 484-91, 1997 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-9075653

RESUMO

BACKGROUND/AIMS: The hepatitis C virus genotypes have been shown to be differently distributed between distinct geographical areas and to be associated with different clinical presentations. In the present study we investigated the distribution of HCV genotypes in 379 German patients with chronic hepatitis C in relation to age, sex, route of infection, liver histology and viremia. METHODS: Typing of HCV was done using restriction fragment length polymorphism analysis as well as a DNA enzyme immunoassay. HCV RNA concentrations were determined by quantitative polymerase chain reaction. Liver biopsies were performed in 187 patients and the histological activity was graded by the Knodell score. RESULTS: Seventy percent were infected with genotype 1 (20% subtype 1a, 80% subtype 1b), 4% with genotype 2 and 26% with genotype 3 (all subtype 3a). Genotype 3a and 1a infection was significantly associated with intravenous drug abuse. In contrast, genotype 1 predominated in patients with post-transfusion hepatitis and infection of unknown origin. A changing relative prevalence of HCV genotypes in relation to age was also observed. Patients with genotype 3 infection showed significantly lower HCV RNA levels and a lower mean histological activity score as compared to patients with genotype 1 and genotype 2. However, using multivariate analysis, only age and mode of transmission but not histological activitiy score were shown to be independent variables. CONCLUSIONS: Our study confirms previous reports from other countries that HCV variants can be classified into a relatively small number of discrete genotypes, and that the subtype 1b clearly predominates. However, we found evidence that there is a changing relative prevalence of HCV genotypes in relation to age, and that the mode of transmission is reflected in the predominance of certain genotypes.


Assuntos
Genes Virais , Hepacivirus/genética , Hepatite C/genética , RNA Viral/análise , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Doença Crônica , Ensaio de Imunoadsorção Enzimática , Feminino , Genótipo , Alemanha , Hepacivirus/imunologia , Hepatite C/etiologia , Hepatite C/transmissão , Anticorpos Anti-Hepatite C/análise , Humanos , Masculino , Pessoa de Meia-Idade , Reação em Cadeia da Polimerase , Prevalência , Fatores de Risco , Abuso de Substâncias por Via Intravenosa/complicações , Reação Transfusional , Viremia/etiologia , Viremia/genética , Viremia/transmissão
11.
Z Arztl Fortbild Qualitatssich ; 91(2): 149-53, 1997 Mar.
Artigo em Alemão | MEDLINE | ID: mdl-9244657

RESUMO

New knowledges about the pathogenesis of HIV-induced immune deficiency syndrome suggest that a change of the natural history of HIV disease by support with antiviral medicaments will be possible. Most important insights are the non-existence of a viral latency phase and the existence of a strong correlation between active viral replication and loss of immunological capacity. Monitoring of HIV replication for detection of efficacy of antiviral therapies is necessary. Potent combinations of antiviral drugs seem to decrease the tendency for development of drug resistant viruses. It seems to be possible to remain healthy for a long time by effective drugs.


Assuntos
Infecções por HIV/reabilitação , Qualidade de Vida , Fármacos Anti-HIV/uso terapêutico , Contagem de Linfócito CD4/efeitos dos fármacos , Terapia Combinada , Quimioterapia Combinada , Infecções por HIV/imunologia , Infecções por HIV/virologia , Humanos , Equipe de Assistência ao Paciente , Prognóstico , Replicação Viral/efeitos dos fármacos
12.
Wien Med Wochenschr ; 147(19-20): 443-4, 1997.
Artigo em Alemão | MEDLINE | ID: mdl-9471840

RESUMO

Sexual exposures every time were associated with increased risks for transmission of infectious agents. In the different kinds of infectious hepatitis actual hepatitis B is sexual transmitted mainly. The most effective prevention is possible by immunization early in the lifetime. Hepatitis C very rarely is sexual transmitted. There is no strong correlation between viral load and risk of transmission by sexual contacts. Like in other infectious diseases including the HIV-infection only the use of condoms and avoiding of unprotected sexual intercourse is the most effective preventive measure.


Assuntos
Hepatite A/transmissão , Hepatite B/transmissão , Hepatite C/transmissão , Hepatite E/transmissão , Doenças Virais Sexualmente Transmissíveis/virologia , Feminino , Hepatite A/prevenção & controle , Hepatite A/virologia , Hepatite B/prevenção & controle , Hepatite B/virologia , Hepatite C/prevenção & controle , Hepatite C/virologia , Hepatite E/prevenção & controle , Hepatite E/virologia , Humanos , Masculino
13.
Scand J Infect Dis ; 29(6): 579-84, 1997.
Artigo em Inglês | MEDLINE | ID: mdl-9571738

RESUMO

Our aim was to establish the frequency and the longitudinal pattern of MAC culture positivity in late stage HIV-infected patients. Two other aims were to analyse risk factors for progression from localized to systemic disease and the value of PCR diagnosis using blood specimens. A total of 107 patients were recruited to be followed for 32 weeks. Prior MAC treatment and CD4 > 100/microliters were exclusion criteria. A total of 56 patients showed M. avium in at least 1 culture. 10/37 patients with MAC detected by culture first in 'non-sterile' specimens (stool, sputum) and urine progressed to systemic disease as determined by positive blood culture. Risk factors associated with this progression were a high symptom score at baseline, lymphadenopathy, anaemia, and low platelets. PCR was less sensitive than culture in detection of M. avium in blood specimens: Only 7/29 patients with positive blood cultures had a positive PCR at the same time. We conclude that symptomatic patients with advanced HIV-infection have a high frequency of MAC detection. Progression from localized to systemic culture positivity is associated with risk factors. Early 'pre-emptive' therapy is discussed.


Assuntos
Síndrome da Imunodeficiência Adquirida/complicações , Complexo Mycobacterium avium , Infecção por Mycobacterium avium-intracellulare/complicações , Reação em Cadeia da Polimerase/métodos , Síndrome da Imunodeficiência Adquirida/microbiologia , Adulto , DNA Bacteriano/isolamento & purificação , Feminino , Humanos , Hospedeiro Imunocomprometido , Masculino , Pessoa de Meia-Idade , Complexo Mycobacterium avium/genética , Complexo Mycobacterium avium/isolamento & purificação , Infecção por Mycobacterium avium-intracellulare/microbiologia , Estudos Prospectivos
15.
Genitourin Med ; 72(3): 176-81, 1996 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-8707318

RESUMO

OBJECTIVE: To study syphilis in HIV infection focusing on immunocompromised patients with an atypical or aggressive clinical course of syphilis, inappropriate serological reactions or an unreliable response to therapy. STUDY DESIGN: A multicentre retrospective chart review using a standardised questionnaire for all patients with active syphilis. SETTINGS: Thirteen dermatological and medical centres throughout Germany, all members of the German AIDS Study Group (GASG). PATIENTS: Clinical data of 11,368 HIV infected patients have been analysed for cases of active syphilis requiring treatment. Asymptotic patients with reactive serological parameters indicating latent syphilis without a need for treatment were excluded. RESULTS: Active syphilis was reported in 151 of 11,368 HIV infected patients (1.33%, range per centre 0.3%-5.1%). Most of the 151 syphilis patients were male (93%) and belonged to the homosexual or bisexual exposure category for HIV infection (79%); another 6% were iv drug users. Among the 151 syphilis patients primary syphilis was diagnosed in 17.2%, maculopapular secondary syphilis in 29.1%, ulcerating secondary syphilis in 7.3%, neurosyphilis in 16.6% and latent seropositive syphilis without clinical symptoms but serological abnormalities indicating active syphilis in 25.2%. A history of prior treatments for syphilis was reported in 50%. At the time of syphilis diagnosis 26.5% of the patients were in CDC stage II, 33.8% in stage III and 24.5% in stage IV of HIV disease (CDC classification 1987). CD4 cell count was lowest in those with ulcerating secondary syphilis (mean 307, SD 140/microliters) and neurosyphilis (351, SD 235/ microliters). The highest CD4 count was found in patients with early primary and early secondary syphilis (444, SD 163/microliters and 470, SD 355/microliters). Inappropriate serological response to syphilis infection was found in 81 of 151 patients (54%). Remarkable findings were false negative VDRL titres (11 patients with non primary syphilis), false negative TPHA (1) or 19S-IgM-FTA-ABS-tests (16), and strongly reactive VDRL (> or = 512, 8) or TPHA titres (> or = 10 240, 47). Treatment failures were reported in at least 6 of 151 cases (4%). CONCLUSIONS: Atypical clinical and serological courses of syphilis were observed in HIV infected patients. Ulcerating secondary syphilis with general symptoms ("malignant syphilis") was 60 times more frequent than in historic syphilis series. Neurosyphilis was found in one sixth of those with active syphilis. Therefore lumbar puncture should be considered a routine in coinfections with HIV and syphilis. Treatment efficacy should be monitored carefully.


Assuntos
Infecções por HIV/complicações , Sífilis/complicações , Adulto , Contagem de Linfócito CD4 , Feminino , Alemanha/epidemiologia , Infecções por HIV/imunologia , Humanos , Hospedeiro Imunocomprometido , Masculino , Estudos Retrospectivos , Sífilis/tratamento farmacológico , Sífilis/epidemiologia , Sorodiagnóstico da Sífilis
16.
Aviat Space Environ Med ; 67(3): 256-61, 1996 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-8775405

RESUMO

BACKGROUND: Evidence in support of the sensory conflict hypothesis for space motion sickness (SMS) is still needed. HYPOTHESIS: We hypothesized that sensory conflict and recovery processes should be demonstrated in intact fish during initial days of microgravity exposure, as a disturbance and restoration of the dorsal light response (DLR; a functional model of visual-graviceptor interaction), respectively. We also expected that this would be true in an otolith-removed fish if it had been fully compensated for dysfunction before the exposure. METHODS: The DLR of carp (Cyprinus carpio) was examined intermittently during the 8-d mission of Spacelab-J. Two carp, normal and labyrinthectomized (LB), made the flight. RESULTS: In the normal carp, the DLR was unstable for the first 3 d inflight but gradually recovered thereafter. The recovery was characterized by gradual restoration of the DLR tilt speed. The LB fish whose otoliths had been removed 2 mo before the flight maintained DLR at the first inflight test session (22 h after launch), but DLR was disrupted at 2 d as in normal fish. The recovery process could not be evaluated in this fish, because the EEG cable which was attached to the fish for supplementary study became tightly twisted and thus immobilized the fish for the remainder of the experiment. CONCLUSION: These findings provided additional evidence in fish for sensory-motor disorder and readjustment during the early phase of microgravity, thus supporting the sensory conflict hypothesis for SMS.


Assuntos
Carpas/fisiologia , Luz , Postura/fisiologia , Sensação/fisiologia , Enjoo devido ao Movimento em Voo Espacial/fisiopatologia , Ausência de Peso , Animais , Comportamento Animal , Cerebelo/fisiologia , Eletroencefalografia
17.
J Travel Med ; 2(4): 213-217, 1995 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-9815393

RESUMO

Background: A considerable number of people remain unprotected against hepatitis B. These people may require immunization at short notice before being exposed to situations or locations where a risk of infection is present. Currently, full active immunization against hepatitis B, when administered according to recommended schedules, takes 2-6 months. This open, randomized multicentric study evaluated the reactogenicity and immunogenicity of a recombinant hepatitis B vaccine in adults when it was administered according to three different rapid vaccination schedules. Methods: Five hundred and twenty four healthy adults (aged 18-59 years) were randomly divided into three groups. Hepatitis B vaccine was given intramuscularly in the deltoid muscle at months 0, 1, and 2 (group A); weeks 0, 14, and 28 (group B); and weeks 0, 7, and 21 (group C). Symptoms were recorded by the subjects on individual diary cards. AntiHBs were measured using radioimmunoassay (Ausab-Abbott); a seroprotective titer was defined as 10 IU/L. Results: At day 28, no significant difference in seroprotection rates (SPRs) i.e., seroconversion >= 10 IU/L,was observed, between groups B (55.6%) and C (65.2%), but both these groups had significantly greater SPRs than group A (15.0%). Although not significant (p=.07), groups B and C also had higher SPRs than group A (78.5% and 76.4% versus 65%) at day 56. One month after completing the three dose schedules, the SPRs were as follows: 89.0% (group A); 78.5% (group B); and 76.4% (group C), increasing to > 94% at month 7 to 8 in all three groups. The SPRs at month 13 were 95.8%, 98.9%, and 98.6%, respectively. Among the three groups, no significant differences were observed from month 2 onwards in either SPRs or geometric mean titers. In groups A, B, and C, 3.7%, 5.0%, and 7.1% of the vaccine injections were associated with local symptoms. Also 8.3%, 6.2%, and 6.3% of subjects exhibited general symptoms following each vaccine dose; all symptoms were transient and resolved spontaneously. Conclusions: This recombinant hepatitis B vaccine administered at weeks 0, 7, 21, or at weeks 0, 14, 28, rapidly elicits high rates of seroprotection, which persist at least until month 12.

18.
Z Arztl Fortbild (Jena) ; 89(3): 229-32, 1995 Jun.
Artigo em Alemão | MEDLINE | ID: mdl-7668009

RESUMO

Since decades, hepatitis A has been a very rare disease in most industrialized countries. According to this, immune reactivity in the adult population is low and susceptibility for the infection is high. Thus, endemic cumlations of hepatitis A diseases are possible. The rate of complications in patients aged over 40 years has increased. Chronic courses in hepatitis A do not exist. There is no specific treatment against the virus. Management of hepatitis A is mainly supportive and symptomatic. There is no indication for steroids. Years ago, a liver diet was the basis of every treatment in every acute hepatitis. This should be refused because there is no reason for this measure.


Assuntos
Hepatite A/epidemiologia , Adulto , Estudos Transversais , Diagnóstico Diferencial , Feminino , Hepatite A/imunologia , Hepatite A/terapia , Hepatovirus/imunologia , Humanos , Imunoglobulina M/sangue , Incidência , Masculino , Pessoa de Meia-Idade
19.
Reg Anesth ; 20(3): 234-8, 1995.
Artigo em Inglês | MEDLINE | ID: mdl-7547661

RESUMO

BACKGROUND AND OBJECTIVES: The needle bevel has an important effect on the path that the needle takes as it traverses tissue. Many anesthesiologists, especially trainees, are unaware of the magnitude of this effect. There is a need for a model, constructed from readily available materials, that can be used to demonstrate the bevel effect and to assess various strategies for accurately advancing the needle. METHODS: Styrofoam blocks were prepared. The following needles were studied: 25-gauge Quincke, 22-gauge Quincke, 18-gauge Quincke, 24-gauge Sprotte, 25-gauge Whitacre, 22-gauge Tuohy, and 17-gauge Tuohy. The effect of bevel orientation on deflection from midline was measured. Representative results were photographed. RESULTS: The bevel has a significant effect on the path of Quincke and Tuohy needles. The deflection is more pronounced for thinner needles. Pencil-point needles show much less deflection than Quincke needles. CONCLUSIONS: Styrofoam blocks provide a model for teaching the basics of spinal and epidural anesthesia. By utilizing styrofoam the trainee can master needle control and gauge the effect of bevel orientation.


Assuntos
Anestesia Epidural/métodos , Raquianestesia/métodos , Agulhas , Anestesia Epidural/instrumentação , Raquianestesia/instrumentação , Anestesiologia/educação , Anestesiologia/instrumentação , Anestesiologia/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...